A Brukinsa regimen has delivered a large progression-free survival (PFS) benefit in what BeOne Medicines called a “new ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating ...

BeOne Medicines Ltd. ONC shares are trading lower on Tuesday as the company shared topline results from its Phase 3 MANGROVE ...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. BeOne Medicines AG (NASDAQ:ONC) is one of the most promising stocks on our list. TheFly reported ...

BeOne Medicines (NASDAQ:ONC) is one of the most promising long-term stocks to buy according to analysts. On June 1, BeOne ...

BeOne Medicines has extended its relationship with Blood Cancer United, committing $5 million over three years to support the ...

BeOne Medicines AG (NASDAQ:ONC) is one of the most promising healthcare stocks according to Wall Street analysts. On June 3, ...

View BeOne Medicines Ltd. Sponsored ADR ONC stock quote prices, financial information, real-time forecasts, and company news from CNN.

BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the class Approval of BEQALZI ...

BeOne Medicines Ltd. (NASDAQ:ONC) on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for up to $950 million ...

BeOne Medicines Ltd ( (HK:6160)) has shared an announcement. BeOne Medicines has detailed the composition of its board of directors and the allocation of responsibilities across five key board ...

BeOne Medicines reports positive results from phase 3 MANGROVE study of Brukinsa in frontline mantle cell lymphoma: San Carlos, California Thursday, July 2, 2026, 10:00 Hrs [IST] ...